Stanley Frankel Buys 2,700 Shares of Precision BioSciences (NASDAQ:DTIL) Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Stanley Frankel acquired 2,700 shares of the stock in a transaction that occurred on Friday, September 26th. The stock was acquired at an average cost of $4.97 per share, for a total transaction of $13,419.00. Following the completion of the transaction, the director directly owned 16,778 shares in the company, valued at $83,386.66. This represents a 19.18% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Precision BioSciences Price Performance

NASDAQ DTIL opened at $5.44 on Thursday. The stock has a 50-day moving average of $4.88 and a 200 day moving average of $4.87. The company has a debt-to-equity ratio of 0.66, a quick ratio of 5.18 and a current ratio of 5.18. The company has a market capitalization of $64.14 million, a price-to-earnings ratio of -0.62 and a beta of 1.71. Precision BioSciences, Inc. has a one year low of $3.61 and a one year high of $9.81.

Precision BioSciences (NASDAQ:DTIL) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($2.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($2.04). The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $6.27 million. Precision BioSciences had a negative net margin of 6,205.79% and a negative return on equity of 176.47%. On average, sell-side analysts forecast that Precision BioSciences, Inc. will post -1.23 EPS for the current year.

Institutional Trading of Precision BioSciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in shares of Precision BioSciences by 5.5% in the 2nd quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock worth $326,000 after buying an additional 4,025 shares in the last quarter. Miller Financial Services LLC purchased a new position in Precision BioSciences during the 1st quarter valued at $48,000. Jane Street Group LLC bought a new stake in shares of Precision BioSciences during the fourth quarter worth $146,000. Tejara Capital Ltd increased its stake in Precision BioSciences by 185.2% in the 1st quarter. Tejara Capital Ltd now owns 60,427 shares of the company’s stock worth $288,000 after buying an additional 39,242 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in shares of Precision BioSciences in the fourth quarter valued at approximately $179,000. 37.99% of the stock is owned by hedge funds and other institutional investors.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.